Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company dedicated to developing life-changing therapies for patients afflicted with cancer and diabetes. The company's mission is to advance novel gene therapies by administering disease-fighting genes to provide new treatment options for large patient populations who currently have limited choices. Founded in 2009, Genprex is headquartered in Austin, Texas.

Genprex's primary oncology product candidate is REQORSA® (quaratusugene ozeplasmid), an immunogene therapy currently undergoing evaluation in multiple clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This therapy leverages the proprietary, non-viral ONCOPREX® Nanoparticle Delivery System. In its diabetes pipeline, Genprex is developing GPX-002, a preclinical gene therapy candidate designed to stabilize glucose levels and reduce insulin requirements in both Type 1 and Type 2 diabetes by delivering Pdx1 and MafA genes to the pancreas.

Genprex has received multiple FDA Fast Track Designations for its lung cancer clinical programs, with its SCLC program also holding an FDA Orphan Drug Designation. Recent developments in early 2026 include the granting of patents in Israel, Japan, and the EU for REQORSA in combination with immunotherapies for cancer treatment. Additionally, positive preclinical data for both REQORSA and the diabetes gene therapy candidate GPX-002 have been presented at scientific meetings. Ryan Confer serves as the President and CEO of the company. Genprex, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol GNPX.

Latest updates

Genprex Bolsters Reqorsa Patent Portfolio with Israel Grant

Event summary

  • Genprex received a patent from the Israel Patent Office covering the use of Reqorsa® Gene Therapy in combination with PD-1 antibodies for cancer treatment.
  • The patent expands Genprex’s existing intellectual property portfolio, which already includes patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.
  • Reqorsa® is currently in development for lung cancer, in combination with existing cancer therapies.
  • Lung cancer incidence and mortality rates are significant in Israel, with lung cancer being the leading cause of cancer death.

The big picture

This patent grant strengthens Genprex’s intellectual property position in a key geographic market, but the company’s success hinges on demonstrating clinical efficacy and navigating the complexities of the oncology drug development process. The combination of gene therapy and PD-1 antibodies represents a growing area of research, and Genprex’s ability to execute on this strategy will be crucial for its long-term viability. The Israeli market, while smaller than others, provides a potential early entry point and validation for the technology.

What we're watching

Market Penetration
The success of Reqorsa in the Israeli market will depend on navigating the country’s healthcare system and demonstrating clinical efficacy compared to existing treatments, given the high lung cancer mortality rate.
Clinical Trial Progress
The pace of clinical trial enrollment and data readouts for Reqorsa in lung cancer will be critical to validating the patent’s value and attracting further investment.
Competitive Landscape
How Genprex differentiates Reqorsa's combination therapy from other emerging immuno-oncology and gene therapy approaches will determine its long-term market positioning.

Genprex Gene Therapy Shows Promise in Preclinical T2D Model

Event summary

  • Genprex collaborators presented preclinical data demonstrating reversal of hyperglycemia in Type 2 diabetic mouse models using Pdx1/MafA gene therapy (GPX-002).
  • The therapy achieved complete rescue of hyperglycemia within four weeks via direct intrapancreatic infusion.
  • The data will be presented at the 2026 ASGCT Annual Meeting in Boston, May 11-15.
  • The therapy utilizes AAV-8 vectors and targets either global islet cells (CMV promoter) or β-cells specifically (RIP).

The big picture

Genprex's preclinical data represents a potentially significant advancement in T2D treatment, moving beyond traditional pharmaceutical interventions towards a gene therapy approach. While the preclinical results are encouraging, the technical challenges associated with localized pancreatic delivery and the competitive landscape in gene therapy for metabolic diseases pose considerable risks. The company's ability to secure regulatory approval and demonstrate long-term efficacy in human trials will be critical to its success.

What we're watching

Clinical Translation
The technical feasibility of translating intrapancreatic infusion via ERCP to a human therapeutic approach remains a significant hurdle, requiring careful assessment of safety and efficacy in clinical trials.
Regulatory Pathway
Given the novel delivery method and gene therapy approach, the regulatory pathway for approval will likely be complex and require extensive discussion with the FDA regarding endpoints and safety protocols.
Competitive Landscape
The emergence of other gene therapy approaches for T2D will likely intensify, requiring Genprex to demonstrate a clear advantage in terms of efficacy, safety, and ease of administration.
CID: 931